guanfacine has been researched along with Body Weight in 11 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The hypotensive action of guanfacine and alpha-methyldopa has been compared in 30 patients wth moderate essential hypertension." | 9.05 | Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. ( Condorelli, M; Rengo, F; Ricciardelli, B; Saccà, L; Trimarco, B; Volpe, M, 1980) |
| "Guanfacine was much more effective than yohimbine." | 5.42 | A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. ( Bednarski, M; Dudek, M; Głuch-Lutwin, M; Kazek, G; Knutelska, J; Mordyl, B; Nowiński, L; Pytka, K; Sapa, J; Zygmunt, M, 2015) |
| " Sixteen patients with essential hypertension were treated with guanfacine and with clonidine for 5 weeks each in a double-blind, placebo-controlled, cross-over trial." | 5.05 | Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine. ( Distler, A; Kirch, W; Lüth, B, 1980) |
| "The hypotensive action of guanfacine and alpha-methyldopa has been compared in 30 patients wth moderate essential hypertension." | 5.05 | Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. ( Condorelli, M; Rengo, F; Ricciardelli, B; Saccà, L; Trimarco, B; Volpe, M, 1980) |
| "Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33." | 2.80 | Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. ( Corcoran, M; Ermer, J; Gastonguay, MR; Knebel, W, 2015) |
| " After a single 2-mg dose, half-life was 14." | 2.73 | Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. ( Boellner, SW; Fiske, K; Lyne, A; Pennick, M; Shojaei, A, 2007) |
| "When guanfacine was tried in 6 very severe hypertensives who had proved resistant to other antihypertensive drugs, a similar reduction in diastolic pressure of 7 mmHg was achieved using a dose of 3 mg daily." | 2.65 | Guanfacine: a new centrally-acting antihypertensive agent. ( Beevers, DG; Bloxham, CA; Walker, JM, 1981) |
| " The dosage administered as milligram per body weight to balance the potential benefits and risks of treatment." | 1.72 | Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Short Communication. ( Fekete, S; Gerlach, M; Högger, P; Romanos, M; Scherf-Clavel, O; Wohkittel, C, 2022) |
| "Guanfacine was much more effective than yohimbine." | 1.42 | A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. ( Bednarski, M; Dudek, M; Głuch-Lutwin, M; Kazek, G; Knutelska, J; Mordyl, B; Nowiński, L; Pytka, K; Sapa, J; Zygmunt, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wohkittel, C | 1 |
| Scherf-Clavel, O | 1 |
| Fekete, S | 1 |
| Romanos, M | 1 |
| Högger, P | 1 |
| Gerlach, M | 1 |
| Siddiqi, SU | 1 |
| Giordano, BP | 1 |
| Dedlow, ER | 1 |
| Knebel, W | 1 |
| Corcoran, M | 1 |
| Ermer, J | 1 |
| Gastonguay, MR | 1 |
| Dudek, M | 1 |
| Knutelska, J | 1 |
| Bednarski, M | 1 |
| Nowiński, L | 1 |
| Zygmunt, M | 1 |
| Mordyl, B | 1 |
| Głuch-Lutwin, M | 1 |
| Kazek, G | 1 |
| Sapa, J | 1 |
| Pytka, K | 1 |
| Boellner, SW | 1 |
| Pennick, M | 1 |
| Fiske, K | 1 |
| Lyne, A | 1 |
| Shojaei, A | 1 |
| Jerie, P | 1 |
| Distler, A | 1 |
| Kirch, W | 1 |
| Lüth, B | 1 |
| Rengo, F | 1 |
| Ricciardelli, B | 1 |
| Volpe, M | 1 |
| Trimarco, B | 1 |
| Saccà, L | 1 |
| Condorelli, M | 1 |
| Beevers, DG | 1 |
| Bloxham, CA | 1 |
| Walker, JM | 1 |
| Gazzola, C | 1 |
| Hunter, RA | 1 |
5 trials available for guanfacine and Body Weight
| Article | Year |
|---|---|
Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Bla | 2015 |
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Age Factors; Area Under Curve; Attention Deficit Disorder wit | 2007 |
Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To | 1980 |
Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension.
Topics: Age Factors; Antihypertensive Agents; Blood Pressure; Body Height; Body Surface Area; Body Weight; D | 1980 |
Guanfacine: a new centrally-acting antihypertensive agent.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; | 1981 |
6 other studies available for guanfacine and Body Weight
| Article | Year |
|---|---|
Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Short Communication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Delayed-Action Prepar | 2022 |
Excessive Weight Gain With Guanfacine: 16.1 Kilograms in 12 Months.
Topics: Adrenergic alpha-2 Receptor Agonists; Body Weight; Child; Guanfacine; Humans; Male; Weight Gain | 2015 |
A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Appetite Dep | 2015 |
Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.
Topics: Antihypertensive Agents; Body Weight; Clonidine; Dose-Response Relationship, Drug; Drug Administrati | 1980 |
The effect of the alpha 2-adrenoceptor agonist, guanfacin, on energy expenditure, intake and deposition in rats.
Topics: Adrenergic alpha-Agonists; Animals; Body Composition; Body Height; Body Weight; Eating; Energy Metab | 1995 |
The effect of the alpha 2-adrenergic agonist, guanfacin, on the energy metabolism of steers fed on low-quality-roughage diets.
Topics: Animals; Body Weight; Cattle; Dietary Fiber; Dose-Response Relationship, Drug; Energy Metabolism; Fa | 1992 |